Exhibit 99.1 Contacts: Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927 Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Third Quarter Fiscal 2024 Financial Results Strong Margin Execution Drives Performance in Quarter • Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growth • GAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectively • Year-to-date Cash from Continuing Operations g ...

Strong Margin Execution Drives Performance in Quarter Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growth GAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectively Year-to-date Cash from Continuing Operations grew 60% to $2.7 billion and Free Cash Flow grew over 100% to $2.2 billion, increasing $1.0 billion and $1.2 billion since the prior year, respectively The company updated its fiscal 2024 GAAP revenue growth guidance t ...

Let's check out the factors that have shaped BDX's performance prior to this announcement. In April, BD's Biosciences business unit announced the global commercial release of the three- and four-laser additions to the BD FACSDiscover S8 Cell Sorter family, which complement the five-laser instrument launched last year. In February, BD announced a strategic partnership with Camtech Health to increase access to cervical cancer screening in Singapore through the country's first-ever program to offer at-home sel ...

Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J., July 25, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best ...

FRANKLIN LAKES, N.J., July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving ...

Becton Dickinson (BDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate ...

More on the News The company has advised customers to prioritize vial use based on clinical needs, following guidelines from the Infectious Disease Society of America and the World Health Organization. While BD does not anticipate a significant financial impact from this issue, it is fully focused on restoring the supply of blood culture vials to normal levels. Price Performance Image Source: Zacks Investment Research Quest Diagnostics, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term g ...

According to the U.S. Census Bureau, the "U.S. population age 65 and over grew nearly five times faster than the total population over the 100 years from 1920 to 2020." Not only that, the older population reached 55.8 million, representing 16.8% of the nation in 2020. Thanks to the post-World War II baby boom, a mass of humanity entered the frame. Brookdale Senior Living (BKD) Still, prospective investors will require some patience. In the past four quarters, the company incurred a loss per share of 19 cent ...

Core Insights - BD (Becton, Dickinson and Company) is addressing a supply issue related to its BACTEC™ blood culture vials, which is not expected to have a material financial impact on the company [1][2][4] - The company is taking measures to mitigate the impact on patient care by manually allocating blood culture vials and advising customers to prioritize usage based on clinical needs [2][4] Company Overview - BD is a leading global medical technology company with a commitment to improving medical discovery, diagnostics, and care delivery [1][3] - The company employs approximately 70,000 individuals and operates in nearly every country, collaborating with organizations to tackle global health challenges [1] Supply Chain Management - The company is experiencing reduced availability of blood culture vials from its supplier and is implementing various strategies to address this issue, including providing manufacturing expertise to the supplier and modifying production schedules [4] - BD is also collaborating with the U.S. Food and Drug Administration to explore options for mitigating supply delays [4] Communication with Stakeholders - BD has communicated with healthcare providers regarding the supply situation and is actively working to ensure that the majority of global demand is met [2][4] - The company has set up a dedicated website for updates on the BACTEC™ blood culture vials supply [5]